SBS says ADMA Biologics investors may seek lead plaintiff role in securities suit
Schall, Brown & Schwartz LLP says investors in ADMA Biologics may contact the firm about lead plaintiff status in a securities class action over alleged misleading statements.
Schall, Brown & Schwartz LLP said investors who bought ADMA Biologics shares during a proposed class period may seek lead plaintiff status in a securities class action that accuses the company of misleading public statements.
The law firm said lead plaintiff status is available to shareholders who purchased stock between Aug. 9, 2024, and March 25, 2026. It also said investors do not need to serve as lead plaintiff to take part in any eventual recovery.
According to the firm's release, the complaint alleges ADMA Biologics, Inc. violated Section 10(b) and Section 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. The release says the complaint claims the company made false and misleading statements, failed to disclose a related-party transaction, used channel stuffing to create the appearance of revenue and did not maintain appropriate internal controls.
The release says the proposed class has not yet been certified. It also identifies ADMA Biologics as NASDAQ: ADMA and says shareholders who bought shares during the class period can contact the firm about possible lead plaintiff appointments.
The press release is dated Aug. 3, 2026, and was issued by Schall, Brown & Schwartz LLP, which described itself as a national shareholder rights litigation firm. The release provides contact information for Brian Schall and David Schwartz in Los Angeles.
What happens next will depend on the court process in the case, including whether the class is certified and whether a lead plaintiff is appointed.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.